Abstract:Background Biliary atresia (BA) is the most common serious neonatal biliary disease, characterized by progressive biliary inflammation and fibrosis. We aim to comprehensively and systematically investigate the complex pathological process of BA from multiple molecular dimensions, combining transcriptomics, proteomics, metabolomics, and single-cell RNA sequencing. Methods Transcriptomic, proteomic, and metabolomic techniques were utilized for detecting and integrating the molecular characteristics of BA liver tissues. By combining single-cell RNA sequencing data, we were able to pinpoint the immune cells regulated by the abnormal metabolite in BA. In vitro experiments were detected to reveal the role and mechanism of the abnormal metabolite signaling pathway in the progression of BA. In vivo, the effect of inhibiting abnormal signaling pathway on alleviating bile duct injury and fibrosis was verified in the rotavirus type A (RRV) induced mouse model. Results We found the aberrant regulation and activation of the sphingolipid metabolism pathway was observed in BA by transcriptomic, proteomic, and metabolomic data analysis. By integrating BA single-cell RNA sequencing data, we found that Sphingosine-1-Phosphate Receptor 4 (S1PR4), a receptor of Sphingosine-1-Phosphate signaling, was primarily expressed in CX3CR1+CD8+ effector T (Teff) cells. In vitro experiments demonstrated that S1P promoted the migration of CX3CR1+CD8+Teff cells, and S1P/S1PR4 signaling facilitated the differentiation of CX3CR1+CD8+Teff cells into CD8+ tissue-resident memory T (TRM) cells. Co-culture of CD8+TRM cells could induce apoptosis of cholangiocytes. In the RRV mouse model, S1PR4 inhibitor could alleviate liver inflammation and fibrosis by inhibiting the accumulation of CD8+TRM cells (IDDF2024-ABS-0207 Figure 1. S1P S1PR4 promotes the differentiation of CD8 TRM cells aggravating bile duct injury in biliary atresia). Conclusions This study used multi-omics data integration to reveal aberrant regulation of the sphingolipid metabolism pathway in BA. The activated S1P/S1PR4 signaling pathway in BA liver recruited CX3CR1+CD8+Teff cells to accumulate around the cholangiocytes. S1P/S1PR4 signaling promoted the differentiation of CX3CR1+CD8+Teff cells into CD8+TRM cells, subsequently triggering apoptosis and injury of cholangiocytes, thus exacerbating the progression of BA. Targeting S1P/S1PR4 signaling activation is a promising therapeutic strategy for BA treatment.

Metabolic regulation of cholestatic liver injury by D-2-hydroxyglutarate with the modulation of hepatic microenvironment and the mammalian target of rapamycin signaling

Metabonomics Reveals Metabolite Changes in Biliary Atresia Infants

Biliary atresia and cholestasis plasma non-targeted metabolomics unravels perturbed metabolic pathways and unveils a diagnostic model for biliary atresia

Correlation between hepatic oxidative damage and clinical severity and mitochondrial gene sequencing results in biliary atresia.

Beta-amyloid Deposition in Biliary Atresia Reduces Liver Regeneration by Inhibiting Energy Metabolism and Mammalian Target of Rapamycin Signaling.

Animal and organoid models to elucidate the anti-fibrotic effect of steroid on biliary atresia

IDDF2024-ABS-0207 S1P/S1PR4 Promotes the Differentiation of CD8+TRM Cells Aggravating Bile Duct Injury in Biliary Atresia

Identification of the Plasma Metabolomics As Early Diagnostic Markers Between Biliary Atresia and Neonatal Hepatitis Syndrome

Progress in Biomarkers Related to Biliary Atresia

Systems Analysis of Biliary Atresia Through Integration of High-Throughput Biological Data

Targeted Metabolomics Reveals Birth Screening Biomarkers for Biliary Atresia in Dried Blood Spots

Mucosal-associated invariant T cells promote ductular reaction through amphiregulin in biliary atresia

Biliary atresia: the role of gut microbiome, and microbial metabolites

Integrative single-cell and spatial transcriptomic analyses identify a pathogenic cholangiocyte niche and TNFRSF12A as therapeutic target for biliary atresia

Distinct Plasma Bile Acid Profiles of Biliary Atresia and Neonatal Hepatitis Syndrome

Liver Immune Profiling Reveals Pathogenesis and Therapeutics for Biliary Atresia

MAPK signaling pathway induced LOX-1+ polymorphonuclear myeloid-derived suppressor cells in biliary atresia

Identifying and validating molecular subtypes of biliary atresia using multiple high-throughput data integration analysis

Upregulation of High Mobility Group Box 1 May Contribute to the Pathogenesis of Biliary Atresia.

Dysregulated Bile Acid Signaling Contributes to the Neurological Impairment in Murine Models of Acute and Chronic Liver Failure

Histamine is correlated with liver fibrosis in biliary atresia.